托瑞米芬治疗子宫体癌的II期研究。初步报告。

A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication.

作者信息

Horváth G, Tropé C, Almbo H E

机构信息

Oncologic Department, Lund University Hospital, Sweden.

出版信息

J Steroid Biochem. 1990 Jun 22;36(3):241. doi: 10.1016/0022-4731(90)90017-m.

DOI:10.1016/0022-4731(90)90017-m

PMID:2142245

Abstract

A phase II study of toremifene was started in patients suffering from advanced carcinoma corporis uteri. Minimum duration of treatment was 3 months but with stabilized disease (SD) and remission the treatment is to be continued as long as the treatment response lasts. At present four patients with recurrent carcinoma corpus uteri have been included. Dose level of toremifene is 200 mg per day. At 12 weeks one of the patients has partial remission (PR), two have SD and one progressive disease (PD). There have been no unacceptable side effects.

摘要

一项针对患有晚期子宫体癌患者的托瑞米芬II期研究已经启动。治疗的最短持续时间为3个月，但对于疾病稳定（SD）和缓解的患者，只要治疗反应持续，治疗就应继续。目前已纳入4例复发性子宫体癌患者。托瑞米芬的剂量水平为每日200毫克。在12周时，其中1例患者部分缓解（PR），2例疾病稳定（SD），1例疾病进展（PD）。未出现不可接受的副作用。